U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

2016
495
Name Type Language
OBILTOXAXIMAB
DASH   INN   USAN   WHO-DD  
INN   USAN  
Official Name English
IMMUNOGLOBULIN G1, ANTI-(BACILLUS ANTHRACIS ANTHRAX PROTECTIVE ANTIGEN) (HUMAN-MUS MUSCULUS MONOCLONAL ETI-204 HEAVY CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL ETI-204 .KAPPA.-CHAIN, DIMER
Common Name English
OBILTOXAXIMAB [USAN]
Common Name English
obiltoxaximab [INN]
Common Name English
OBILTOXAXIMAB [PURPLE BOOK CDER]
Common Name English
OBILTOXAXIMAB [MI]
Common Name English
ANTHIM
Brand Name English
Obiltoxaximab [WHO-DD]
Common Name English
ETI-204
Code English
Classification Tree Code System Code
FDA ORPHAN DRUG 224306
Created by admin on Sat Dec 16 09:11:02 UTC 2023 , Edited by admin on Sat Dec 16 09:11:02 UTC 2023
NDF-RT N0000192703
Created by admin on Sat Dec 16 09:11:02 UTC 2023 , Edited by admin on Sat Dec 16 09:11:02 UTC 2023
WHO-ATC J06BB22
Created by admin on Sat Dec 16 09:11:02 UTC 2023 , Edited by admin on Sat Dec 16 09:11:02 UTC 2023
EU-Orphan Drug EU/3/18/2065
Created by admin on Sat Dec 16 09:11:02 UTC 2023 , Edited by admin on Sat Dec 16 09:11:02 UTC 2023
Code System Code Type Description
DAILYMED
29Z5DNL48C
Created by admin on Sat Dec 16 09:11:02 UTC 2023 , Edited by admin on Sat Dec 16 09:11:02 UTC 2023
PRIMARY
RXCUI
1746906
Created by admin on Sat Dec 16 09:11:02 UTC 2023 , Edited by admin on Sat Dec 16 09:11:02 UTC 2023
PRIMARY
MERCK INDEX
m11939
Created by admin on Sat Dec 16 09:11:02 UTC 2023 , Edited by admin on Sat Dec 16 09:11:02 UTC 2023
PRIMARY
ChEMBL
CHEMBL3544926
Created by admin on Sat Dec 16 09:11:02 UTC 2023 , Edited by admin on Sat Dec 16 09:11:02 UTC 2023
PRIMARY
USAN
ZZ-114
Created by admin on Sat Dec 16 09:11:02 UTC 2023 , Edited by admin on Sat Dec 16 09:11:02 UTC 2023
PRIMARY
SMS_ID
100000182406
Created by admin on Sat Dec 16 09:11:02 UTC 2023 , Edited by admin on Sat Dec 16 09:11:02 UTC 2023
PRIMARY
HSDB
8336
Created by admin on Sat Dec 16 09:11:02 UTC 2023 , Edited by admin on Sat Dec 16 09:11:02 UTC 2023
PRIMARY
WIKIPEDIA
Obiltoxaximab
Created by admin on Sat Dec 16 09:11:02 UTC 2023 , Edited by admin on Sat Dec 16 09:11:02 UTC 2023
PRIMARY
NCI_THESAURUS
C166561
Created by admin on Sat Dec 16 09:11:02 UTC 2023 , Edited by admin on Sat Dec 16 09:11:02 UTC 2023
PRIMARY
NDF-RT
N0000192702
Created by admin on Sat Dec 16 09:11:02 UTC 2023 , Edited by admin on Sat Dec 16 09:11:02 UTC 2023
PRIMARY Anthrax Protective Antigen-directed Antibody Interactions [MoA]
FDA UNII
29Z5DNL48C
Created by admin on Sat Dec 16 09:11:02 UTC 2023 , Edited by admin on Sat Dec 16 09:11:02 UTC 2023
PRIMARY
DRUG CENTRAL
5094
Created by admin on Sat Dec 16 09:11:02 UTC 2023 , Edited by admin on Sat Dec 16 09:11:02 UTC 2023
PRIMARY
LACTMED
Obiltoxaximab
Created by admin on Sat Dec 16 09:11:02 UTC 2023 , Edited by admin on Sat Dec 16 09:11:02 UTC 2023
PRIMARY
CAS
1351337-07-9
Created by admin on Sat Dec 16 09:11:02 UTC 2023 , Edited by admin on Sat Dec 16 09:11:02 UTC 2023
PRIMARY
DRUG BANK
DB05336
Created by admin on Sat Dec 16 09:11:02 UTC 2023 , Edited by admin on Sat Dec 16 09:11:02 UTC 2023
PRIMARY
INN
9825
Created by admin on Sat Dec 16 09:11:02 UTC 2023 , Edited by admin on Sat Dec 16 09:11:02 UTC 2023
PRIMARY
ACTIVE MOIETY
OBILTOXAXIMAB
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966